Home' Australian Pharmacist : January 2011 Contents Vol.30–January#01
of medication use by high-risk patients,
more exchange between doctors and
pharmacists, and increased use of
technology for medication assessment
‘The medication use of high-risk
patients (e.g . elderly patients
with polypharmacy) should be
reviewed regularly for potential
such as underprescription and
and user convenience. Such an
evaluation should also include
a cognitive assessment and
identification of barriers for
medication regimen adherence and
should provide tools to facilitate
the proper use of medication. The
patient should be actively involved
in this process and should be given
his or her own responsibility in
achieving treatment goals. Second,
we recommend that physicians
and pharmacists exchange more
information relevant to adequate
medication surveillance, such as
comorbidities and clinical laboratory
data (e.g . renal function).’
This very much sounds like Australia’s
unique schemes of Home Medicines
Reviews (HMRs) and Residential
Medication Management Reviews
(RMMRs). Better collaboration
between doctors, patients and
pharmacists should be readily
possible in Australia. The planned
improvements to the HMR referral
pathway under the Fifth Community
Pharmacy Agreement should benefit
elderly Australians, our health care
system and the pharmacy profession.
Strategically, Australian community
pharmacists must focus their attentions
on medication-related adverse events,
especially in the elderly, and fervently
grasp and highlight the role of being
advocates for patient safety.
1. Roughead EE, Semple SJ. Medication safety in acute care
in Australia: where are we now? Part 1: a review of the
extent and causes of medication problems 2002–2008.
Aust New Zealand Health Policy. 2009; 6:18.
2. Semple SJ, Roughead EE. Medication safety in acute
care in Australia: where are we now? Part 2: a review of
strategies and activities for improving medication safety
2002–2008. Aust New Zealand Health Policy. 2009; 6:24.
3. Burgess CL, Holman CD, Satti AG. Adverse drug reactions
in older Australians, 1981–2002. Med J Aust. 2005;
4. Schneider EL, Campese VM. Adverse drug responses: An
increasing threat to the well-being of older patients. Arch
Intern Med. 2010; 170(13):1148–9.
5. Jyrkka J, Vartiainen L, Hartikainen S, et al. Increasing
use of medicines in elderly persons: a five-year follow-
up of the Kuopio 75+Study. Eur J Clin Pharmacol. 2006;
6. Caughey GE, Roughead EE, Vitry AI, et al. Comorbidity
in the elderly with diabetes: Identification of areas of
potential treatment conflicts. Diabetes Res Clin Pract.
2010; 87(3):385–93 .
7. Ruiz B, Garcia M, Aguirre U, et al. Factors predicting
hospital readmissions related to adverse drug reactions.
Eur J Clin Pharmacol. 2008; 64(7):715–22.
8. Sanchez Munoz-Torrero JF, Barquilla P, Velasco R, et al.
Adverse drug reactions in internal medicine units and
associated risk factors. Eur J Clin Pharmacol. Published
online 6 Aug 2010. DOI: 10.1007/s00228-010-0866–6 .
9. Leendertse AJ, Egberts AC, Stoker LJ, et al. Frequency
of and risk factors for preventable medication-related
hospital admissions in the Netherlands. Arch Intern Med.
10. Zopf Y, Rabe C, Neubert A, et al. Risk factors associated
with adverse drug reactions following hospital admission:
a prospective analysis of 907 patients in two German
university hospitals. Drug Saf. 2008; 31(9):789–98 .
11. Onder G, Petrovic M, Tangiisuran B, et al. Development
and validation of a score to assess risk of adverse drug
reactions among in-hospital patients 65 years or older:
the GerontoNet ADR risk score. Arch Intern Med. 2010;
12. Zhang M, Holman CD, Price SD, et al. Comorbidity and
repeat admission to hospital for adverse drug reactions
in older adults: retrospective cohort study. BMJ. 2009;
13. Begaud B, Martin K, Fourrier A, et al. Does age increase
the risk of adverse drug reactions? Br J Clin Pharmacol.
The Accredited Pharmacist Special
Interest Group (APSIG) provides specifically
targeted support for accredited pharmacists
to raise their questions, issues, concerns or
success stories on practice or remuneration
issues, clinical news, communication and case
discussion. It is an excellent opportunity to get
input and feedback from colleagues across the
country and find out about the latest issues
affecting accredited pharmacists.
Are you an
Join the PSA Accredited
Interest Group today!
Being a member of APSIG provides you with
support and education through:
• APSIG clinical seminars and discussion groups – currently being run in SA, Vic and Tas,
these education evenings give you the opportunity to network with other accredited
pharmacists, discuss case examples and increase your clinical knowledge.
• APSIG discussion forum – this online discussion forum hosted on the PSA website enables
you to ask those burning clinical, business and process questions and gain practical advice
from your peers.
• APSIG webpages – the APSIG section of the PSA member’s only website lists all the
upcoming CPD events that might be of interest to accredited pharmacists.
• APSIG National Committee – the APSIG National Committee consists of a representative
from each state and meets several times a year to discuss how PSA can further support
the needs of accredited pharmacists. If you would like to raise an issue related to being
an accredited pharmacist, contact your state APSIG National Committee representative.
Contact details for state representatives are included on the APSIG webpages.
• Networking opportunities at conferences such as Pharmacy Australia Congress (PAC)
• Email alerts on events of relevance to you.
If you are an accredited pharmacist, or interested in being an accredited pharmacist,
why not join APSIG today. Email APSIG@psa.org.au quoting your PSA member number
to gain access to the range of support provided to APSIG members.
Pharmaceutical Society of Australia, PO Box 42, Deakin West ACT 2600
Tel: 02 6283 4777 | Fax: 02 6285 2869 | Email: APSIG@psa.org.au
Links Archive Australian Pharmacist February 2011 Navigation Previous Page Next Page